ABSTRACT Tourette syndrome (TS) is an inherited developmental neuropsychiatric disorder characterized by vocal and motor tics. Multiple lines of neurophysiological evidence implicate dysfunction in the corticostriatal
further enriched in the somatodendritic compartment and cytoplasmic vesicles of cortical pyramidal neurons in mouse, monkey, and human brain, observations suggestive of an evolutionarily conserved function in mammals. SLITRK1 is transiently expressed in the striosomal/patch compartment of the mammalian striatum and moreover is associated with the direct output pathway; adult striatal expression is confined to cholinergic interneurons. These analyses demonstrate that the expression of SLITRK1 is dynamic and specifically associated with the circuits most commonly implicated in TS and related disorders, suggesting that SLITRK1 contributes to the development of corticostriatal-thalamocortical circuits. J. Comp Here we demonstrate that the expression of SLITRK1 is developmentally regulated in mouse, monkey, and human brain. SLITRK1 is detected in layer 3, 5, and 6 cortical pyramidal neurons that participate in corticocortical, corticothalamic, and corticostriatal circuits and is moreover associated with the apical dendrite. In the striatum, SLITRK1 expression is high in striosomes/patches during early brain development but significantly diminished later, suggesting a possible role in establishing the corticostriatal circuitry. It is further restricted to striatal projection neurons of the direct pathway. These results confirm developmentally regulated expression of SLITRK1 in the neuroanatomical circuits most commonly implicated in TS and related disorders and offer insights into the potential function(s) of this protein in brain development and pathogenesis.
MATERIALS AND METHODS Mice
Experiments were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee at Yale University School of Medicine. Adult CD1 mice (older than 3 months) were purchased from Charles River Laboratories (Wilmington, MA). Mouse colonies were maintained at Yale University, in compliance with National Institutes of Health guidelines and with the approval of Yale University Institutional Animal Care and Use Committee. For timed pregnancies, midday of the day of vaginal plug discovery was considered embryonic (E) day 0.5. Mice at embryonic and postnatal stages through adulthood were used. For embryonic stages, pregnant females were anesthetized, and pups at appropriate stages were extracted from the uterus. Embryonic brains were dissected and fixed by immersion in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS), pH 7.4.
Mouse pups [postnatal (P) day 0 through P2] were deeply anesthetized on ice, and then the brains were removed and fixed in 4% PFA. At all other stages, mice were anesthetized with injectable anesthetics (100 mg/kg ketamine and 10 mg/kg xylazine) and intracardially perfused with 4% PFA. . To obtain the embryo, a caesarean section was performed as previously described (Rakic and Goldman-Rakic, 1985) . In short, the pregnant monkey was first sedated with ketamine (3 mg/kg) and atropine sulfate (Lilly; 0.2 mg/kg). A catheter was introduced into the saphenous vein for continuous administration of fluids. Surgery was performed aseptically under halothane-nitrous oxide-oxygen anesthesia. Postoperatively, the animal was administered painkillers, and the wound was periodically cleaned. The animal was monitored until full recovery. The adult monkeys had been retired from a breeding colony in the Department of Neurobiology, in compliance with National Institutes of Health guidelines and with the approval of Yale University Institutional Animal Care and Use Committee.
Human and monkey brain specimens

In situ hybridization
Mouse brains were removed, postfixed overnight in 30% sucrose/4% PFA, and sectioned in the coronal plane on a Leica sledge cryomicrotome at 36 m (Leica Microsystems, Wetzlar, Germany). Sections were mounted on slides and processed for nonradioactive in situ hybridization as described previously, with minor modifications (Tole and Patterson, 1995; Grove et al., 1998 ). An RNA probe complementary to mouse Slitrk1 (bases 322-1383 of the mouse Slitrk1 cDNA, NM_199065) was prepared and labeled with digoxigenin-11-UTP. Sections were analyzed with a Zeiss Stemi dissecting microscope or a Zeiss AxioImager (Zeiss, Oberkochen, Germany) fitted with an AxioCam MRc5 digital camera. Images were captured using AxioVision AC software (Zeiss) and assembled in Adobe Photoshop.
Antibody characterization
All antibodies used in this study were individually examined following immunostaining of mouse brain sections by confocal microscopy to ensure that the signal appeared specific and was concordant with known information about the protein. Additional information about each antibody is listed in Table 1 .
The B-cell CLL/lymphoma 11B (BCL11B) antibody detected two bands of ϳ120 kD molecular weight corresponding to the two splice variants of BCL11B on Western blots of Jurkat cell lysates (manufacturer's technical information) and detected The calbindin 2 (CALB2; calretinin-22k) antibody recognized a common epitope for both calretinin and calretinin-22k (a region between EF-hand domains III and IV) on Western blots of mouse and rat brain extracts and dot blots (Zimmermann and Schwaller, 2002) and stained a pattern of cellular morphology and distribution in mouse brain sections identical to that in previous reports (Brandt et al., 2003) and to the authors' unpublished observations. The choline acetyltransferase (ChAT) antiserum specifically recognized a band of 68 kD m.w. in the ammonium sulfate fraction of placental proteins supplemented with affinitypurified placental ChAT but not in that fraction alone (Bruce et al., 1985) and immunoprecipitated a 68-kD protein that displayed ChAT enzymatic activity from brain and placenta protein extracts; it also precipitated a 27-kD protein that is coexpressed with ChAT but lacks ChAT activity in some cholinergic neurons of the central nervous system (manufacturer's technical information). This antiserum stained cholinergic neurons in rat cerebral cortex (Lysakowski et al., 1989) . The authors independently assessed the staining pattern in mouse basal ganglia sections and found it identical to previous reports (Gabriel and Witkovsky, 1998); furthermore, preincubation with recombinant rat ChAT protein abolished staining of large striatal neurons with morphology characteristic of cholinergic interneurons.
The D 1 dopamine receptor antiserum specifically recognized a band of ϳ50 kD m.w. on Western blots of membrane protein extracts from rat striatum and cerebellum (manufacturer's technical information); the authors independently assessed the staining pattern in mouse brain sections and found it identical to that in previous reports (Levey et al., 1993; Yung et al., 1995) .
The enkephalin antiserum was tested for specificity by immunohistochemistry; staining was eliminated by preincubation with the immunizing peptide. The antiserum stained a pattern of cellular morphology and distribution in mouse brain sections that is identical to that in previous reports (Holt and Newman, 2004) . 
Immunohistochemistry
Embryonic, postnatal, and adult mouse brains were collected and fixed as described above, cryoprotected in 30% sucrose in PBS, sectioned at 40 m using a sledge microtome in the coronal plane, and processed freely floating. Fetal and adult monkey and human brains were fixed in 4% PFA, cryoprotected in 30% sucrose, frozen by immersion in 2-methylbutane, and stored at -80°C. Blocks were sectioned frozen at 60 m with a cryostat and processed freely floating.
For diaminobenzidine (DAB) staining with the goat anti-SLITRK1 antibody, sections of embryonic, postnatal, or adult mouse and of fetal or adult monkey and human brain were treated with 1% H 2 O 2 ; washed in PBS; and preincubated in blocking solution (BS) containing 5% normal donkey serum (Jackson Immunoresearch Laboratories, West Grove, PA), 1% BSA, 0.1% glycine, 0.1% L-lysine, and 0.03% Triton X-100. The sections were then incubated with anti-SLITRK1 antibody for 36 hours at 4°C. After washes with PBS, the sections were incubated with secondary antibody [donkey anti-goat Biotin-SP (Jackson Immunoresearch Laboratories; 1:250 dilution)] for 2 hours at room temperature, washed in PBS, and then incubated with Vectastain ABC Elite solution (Vector, Burlingame, CA) for 2 hours. Sections were developed with 0.05% DAB (pH 7.4), 0.2% glucose, 0.01% nickel ammonium sulfate, 0.04% ammonium chloride, and 8 g/ml glucose oxidase and then rinsed, mounted onto glass slides, allowed to dry, dehydrated, and coverslipped. For double staining with the goat anti-SLITRK1 and mouse anti-ChAT antibodies, adult mouse, monkey, and human brain sections were first incubated with the anti-SLITRK1 antibody and processed for DAB staining as described, followed by incubation with the antiChAT antibody for 36 hours at 4°C, washes in PBS, incubation with secondary antibody [horserasdish peroxidase (HRP)-conjugated donkey anti-mouse IgG (Vector, 1:200 dilution)] for 2 hours, washes in PBS, and then incubation with Vectastain ABC peroxidase solution (Vector) for 2 hours. Sections were developed using Nova Red peroxidase substrate (Vector) and then rinsed, mounted onto glass slides, allowed to dry, dehydrated, and coverslipped.
For immunofluorescence, mouse brain sections were placed in BS without H 2 O 2 treatment and then incubated in primary antibodies for 36 hours at 4°C. Secondary antibodies were all highly cross-absorbed, raised in donkey, conjugated to cyanine 2 (Cy2) or Cy3 (Jackson Immunoresearch Laboratories), and used at 1:250 dilution in BS without Triton X-100 for 2 hours at room temperature. The sections were mounted, coverslipped with DAPI-containing Vectashield (Vector), and analyzed with a confocal microscope (Zeiss).
Image capture and analysis
Tissue sections were photographed by using a Zeiss AxioImager fitted with a Zeiss AxioCam MRc5 digital camera. Images were captured by using AxioVision AC software (Zeiss) and assembled in Adobe Photoshop. Some images were modified to adjust contrast (see Fig. 9 ). For confocal microscopy, single optical and z-stack images were collected on a Zeiss LSM 510 laser-scanning microscope and assembled in Adobe Photoshop.
Western blotting
Adult human brain protein extracts (Human Brain Protein Medley) were obtained from Clontech Laboratories (Mountain View, CA). Adult mouse brains were dissected and homogenized in lysis buffer [10 mM Tris, 200 mM NaCl, 1 mM EDTA (pH 7.4), 2% SDS] containing protease inhibitors (Roche Applied Science, Indianapolis, IN). Fifty-microgram protein samples were analyzed via SDS-PAGE under reducing conditions with a 4 -15% gradient polyacrylamide gel. Western blotting was performed with anti-SLITRK1 antibody (dilution 1:1,000) and HRP-conjugated donkey anti-goat secondary antibody (dilution 1:5,000); the signal was detected by using a chemilluminescence system (ECL Western Blotting Detection system; GE Healthcare Bio-Sciences Corp., Piscataway, NJ). The blots were stripped with 2% SDS and ␤-mercaptoethanol and reprobed with HRP-conjugated anti-␤-actin (1:5,000; Sigma, St. Louis, MO) for loading control. For peptide competition analyses, the primary goat anti-SLITRK1 antibody was preabsorbed at a 1:5 ratio with the corresponding immunizing peptide (R&D Systems) at room temperature for 2 hours prior to application for both immunostaining and Western blot assays. 
Immunogold labeling and electron microscopy
Retrograde tracing
Adult mouse brains were stereotaxically injected with the retrograde tracers (Retro Beads; Lumafluor, Naples, FL) or BDA-3k (dextran-3000 MW conjugated to tetramethylrhodamine; Molecular Probes, Eugene, OR) into the contralateral neocortex and ipsilateral caudate-putamen (i.e., striatum) and thalamus (lateral posterior nucleus). After 7 days, the animals were killed, and brains were processed for immunofluorescence with anti-SLITRK1 antibody.
RESULTS
SLITRK1 is developmentally regulated in the corticostriatal-thalamocortical circuits
We studied Slitrk1 mRNA expression in the embryonic and postnatal mouse brain using in situ hybridization and placing emphasis on corticostriatal-thalamocortical pathway components given their likely role in the pathophysiology of TS. Slitrk1 mRNA was first detected at E8.75 in a restricted domain of the ventral neural tube at the level of the midbrain/ hindbrain boundary. This expression domain was maintained and spread both anteriorly and posteriorly over the next 2 days, so that, by E11.5, Slitrk1 mRNA was detected in the ventral midencephalon/diencephalon, telencephalon, and hindbrain (data not shown). In the developing neocortex, by E14.5, Slitrk1 expression was confined to the cortical plate but was absent from the proliferating progenitors in the ventricular zone. Low levels of expression were evident in the intermediate zone, and this pattern was maintained in late embryogenesis (Fig. 1A,B) . Embryonic expression was also prominent in the developing septal area, basal ganglia (Fig.  1A,C), globus pallidus (Fig. 1A,D), thalamus (Fig. 1A,E) , hypothalamus, midbrain, mesopontine area, cerebellum, medulla, and spinal cord (data not shown).
In the developing and adult cortex, Slitrk1 was highly expressed in prospective and mature cortical layers 3, 5, and 6, which contain pyramidal projection neurons (Fig.  1F,G,K,L,P,Q) . In the developing dorsal and ventral thalamus, Slitrk1 was expressed broadly (Fig. 1A,E) and became gradually refined to subsets of prospective nuclei that included, at postnatal stages, the reticular nucleus; midline and intralaminar nuclei; mediodorsal, laterodorsal, and parafascicular nuclei; and ventral lateral and ventral posterior complex; expression in the ventral lateral and ventral anterior nuclei diminishes in the adult (Fig. 1F,J,K,O,P,T) . In the striatum, Slitrk1 expression changed significantly during development. Initially dif- fuse, it became compartmentalized with a patchy distribution at P2 (Fig. 1H) , remaining particularly prominent through P7 (Fig. 1A,C,F,H,K,M) , and then decreased markedly, with only a few striatal neurons showing any evidence of expression at P14; Slitrk1 mRNA was undetectable by P21 and into adulthood in all but a few neurons (Fig. 1P,R , and data not shown). Slitrk1 mRNA was also present in the nucleus accumbens until P21 but not in the adult; in the globus pallidus and the substantia nigra pars compacta, expression was detected throughout development and into adulthood (Fig. 1A,D,  F,I,K,N,P,S, and data not shown) .
We next examined the distribution of the SLITRK1 protein by immunohistochemistry with a commercially available antibody raised against the extracellular domain of human SLITRK1 (see Materials and Methods). Consistently with our in situ hybridization findings, we detected SLITRK1 in the cortical plate in future layers 3, 5, and 6 (Fig. 2A) ; this pattern was elaborated postnatally and maintained through adulthood (Fig. 2D,G,J) . SLITRK1 was confined to the somatodendritic compartment of cortical pyramidal neurons, but its relative distribution evolved as development proceeded. In embryonic and early postnatal cortex, SLITRK1 was expressed primarily in apical dendrites (Fig. 2B,E) , including the dendritic terminal tufts in the marginal zone; low levels of protein were also detected in the cell body during this period. A shift in expression from the apical dendrites toward the neuronal cell body was evident by P7, where it was primarily confined in the adult, outlining a distinct pyramidal cell shape (Fig. 2H,K) and appearing in an asymmetric, or polarized, pattern within the cell; low levels of expression persisted in the apical dendrites. Protein distribution in the striatum was in accordance with the mRNA expression profile: although diffuse in embryogenesis (Fig. 2C) , SLITRK1 appeared compartmentalized in the neonatal striatum (Fig. 2F) , assuming a patch-like distribution, especially evident at early postnatal stages (Fig. 2I) . After the second postnatal week, expression levels diminished significantly, and, in adult mouse striatum, only a few cells appeared to sustain SLITRK1 expression (Fig. 2L) . SLITRK1 expression was further detected in the adult globus pallidus, subthalamic nucleus, and substantia nigra pars compacta (Fig. 3A,B,D-F) .
Taken together, these observations demonstrate that SLITRK1 is developmentally regulated. In the cortex, the balance of expression in the somatodendritic compartment shifts from primarily dendritic early to mainly somatic postnatally, possibly reflecting a role in dendritic maturation; in the striatum, SLITRK1 is detected in a specific developmental time window coinciding with the establishment and elaboration of the corticostriatal circuit and is subsequently down-regulated. In the thalamus, SLITRK1 is detected in sensory, association, nonspecific, and motor nuclei, implying its presence in thalamocortical neurons.
SLITRK1 expression in cortex and striatum is conserved across mammalian species
We further examined SLITRK1 protein distribution in both fetal and adult rhesus monkey as well as human brain and found many similarities to what was seen in mouse, suggesting a conserved function of the protein. In the neocortex at fetal stages, expression was detected in apical dendrites (Fig.  4A,B,G,H) , whereas, in adults, SLITRK1 appeared localized in the cell body of pyramidal neurons, in addition to the apical dendrites (Fig. 4D,E,J,K) . In both species, SLITRK1 was expressed mainly in layers 3, 5, and 6, with little or no staining detected in layers 1 and 2. As in mouse, in fetal monkey and human striatum SLITRK1 protein distribution was compartmentalized in structures reminiscent of striosomes (Fig. 4C,I) ; with the exception of a few cells, the protein was undetectable in the adult striatum in both species (Fig. 4F,L) , which is consistent with our observations in mouse. Thus, for striatum, we also observed similar developmental regulation of SLITRK1 expression in all three mammalian species examined, with the window of expression coinciding with the establishment and elaboration of corticostriatal connections.
SLITRK1 is restricted to cortical projection neurons
To characterize further the cortical projection neurons that express SLITRK1, we performed colocalization studies with cell-type-specific markers in P7 mouse cortex. SLITRK1 colocalized with SMI32, a marker of pyramidal neurons with long axonal projections (Campbell and Morrison, 1989; Fig. 5A ). Within layer 5, SLITRK1 was expressed in all neurons expressing BCL11B/CTIP2 (Fig. 5B) (Fig. 5D) . On the other hand, interneuron-specific markers revealed no colocalization in the cortex: SLITRK1 was absent from GABAergic interneurons and other interneuron subtypes expressing nitric oxide synthase (NOS), parvalbumin (PVALB), or CALB2/calretinin (Fig. 5E-H) . Finally, there was no overlap of SLITRK1 with the astroglial marker GFAP (Fig. 5I) .
To determine the projection targets of SLITRK1-expressing cortical neurons, we combined retrograde axonal tracing using fluorescent microspheres (Retro Beads) or BDA-3k with anti-SLITRK1 immunofluorescence. In adult mouse cortex, SLITRK1 protein was detected in retrogradelly labeled neurons with axonal projections to the contralateral cortex, ipsilateral striatum, and thalamus (Fig. 6A-C , and data not shown), demonstrating that SLITRK1 is selectively expressed in the cortical projection neurons that make up the corticostriatal-thalamocortical circuitry.
SLITRK1 subcellular localization in cortical neurons
We examined the subcellular localization of SLITRK1 in the cerebral cortex of adult mouse and rhesus monkey by using immunoelectron microscopy. In both species, we detected SLITRK1 in neuronal dendrites, the periphery of the Golgi 
SLITRK1 is confined to the striosomes and the direct pathway
Our in situ hybridization and immunostaining results suggested that Slitrk1 mRNA and SLITRK1 protein in the striatum were compartmentalized. Consequently, we used cell-typespecific markers to characterize SLITRK1-expressing cells in mouse striatum at P7. SLITRK1-positive cells expressed the -opiate receptor, which is greatly enriched in the striosomes (Herkenham and Pert, 1981; Fig. 8A-C) . Additionally, SLITRK1 was expressed in medium-spiny neurons also expressing substance P (Fig. 8D-F) and the D 1 dopamine receptor (Fig.  8G-I) , established markers of direct pathway striatal neurons projecting to the medial globus pallidus and the substantia nigra, but not in those expressing the indirect pathway marker enkephalin (Gerfen and Young, 1988; Fig. 8J-L) . SLITRK1 was further absent from GABA-ergic interneurons, including those expressing PVALB, CALB2, or NOS1 (not shown). Furthermore, SLITRK1 was highly expressed in the globus pallidus, the thalamic parafascicular and lateral dorsal nuclei, and the substantia nigra pars compacta but was absent from the subthalamic nucleus and the substantia nigra pars reticulata, contributing to the overall presence of SLITRK1 in the direct rather than the indirect pathway of the basal ganglia (Fig.  3A-F, and data not shown) . As mentioned above, a few neurons in the adult striatum appeared to maintain Slitrk1 mRNA and SLITRK1 protein expression (Fig. 9A-C) . These were large, of modest numbers, and scattered throughout the striatum, characteristics suggesting that they might be giant cholinergic interneurons. Double labeling with anti-SLITRK1 and anti-ChAT antibodies confirmed that in the adult mouse (Fig. 9D),  monkey (Fig. 9E), and human (Fig. 9F) 
DISCUSSION
These studies demonstrate that SLITRK1 expression during mammalian brain development is both developmentally regulated and evolutionarily conserved. In the cortex, SLITRK1 is expressed primarily in pyramidal projection neurons and remains confined within the somatodendritic compartment, where its distribution shifts from primarily dendritic to mainly somatic as the brain matures, possibly reflecting a role in the elaboration of apical dendrites. SLITRK1 is associated with cytoplasmic vesicles in both mouse and monkey neocortex, suggesting that it might be secreted. In the striatum, SLITRK1 is transiently expressed in projection neurons of the direct output pathway and concentrated in striosomes during early brain development, consistent with a role in establishing striatal connectivity; expression is maintained only in adult cholinergic interneurons. This general pattern is observed in monkey and human brain as well, maintained in cell types and subcellular compartments, with this high degree of conservation suggesting a preserved function of the SLITRK1 protein across mammalian species.
Potential role for SLITRK1 in cortical dendritic development
SLITRK1 is expressed by cortical pyramidal neurons in layers 3, 5, and 6 in mouse, rhesus monkey, and human brain. These project both intracortically (3) and subcortically (5 and 6) to the striatum and thalamus, thus placing SLITRK1 in the corticostriatal-thalamocortical pathway. SLITRK1 is confined to the somatodendritic compartment, where its distribution is developmentally regulated: early, it is expressed highly in the apical dendrite and at lower levels in the cell body; by the end of the first postnatal week, it appears concentrated in the soma and is detected only at lower levels in the apical dendrite. Within the adult cortical neuronal cell body, SLITRK1 is asymmetrically distributed. These expression patterns are striking; however, the functional implications are presently unknown. Overexpression of SLITRK1 elicits unipolar neurites in cell lines ( 
Possible roles for SLITRK1 in striatal circuitry
In the striatum, SLITRK1 is initially broadly expressed, is subsequently concentrated in striosomes in embryonic and early postnatal development, and is undetectable by adulthood, with the notable exception of cholinergic interneurons. During the first 2 postnatal weeks, SLITRK1 appears to be confined to two compartmentalized systems within the striatum: the direct pathway neurons and the striosomes; this segregation possibly implies a functional role for the protein in a subset of developing medium-spiny projection neurons.
Afferent inputs terminate largely on dendritic spines of striatal medium spiny neurons, and, if SLITRK1 is indeed generally involved in dendritic regulation, as suggested by both the effects of its overexpression in primary cortical pyramidal neurons and its localization in the apical cortical dendrite, these terminals may also represent potential sites of SLITRK1 function. Moreover, SLITRK1 may influence dendritic development in the medium-spiny neurons that express it in a manner dependent on nigrostriatal dopaminergic and/or thalamostriatal afferent input. In mouse striatum, dendritic maturation is initiated in the first postnatal week (Sturrock, 1980) , a period of high expression of the SLITRK1 protein, in a temporal profile following closely the same process in cortical pyramidal cells (Miller, 1981; Petit et al., 1988) . GP (while also extending collaterals to the lateral GP). In rodents, direct-pathway neurons constitute approximately half of the striatal projection neuron population, are intermingled with indirect neurons (projecting only to the lateral GP) throughout the striatum, and are equally distributed in patches and matrix (Gerfen, 2004) . Therefore, SLITRK1 expression appears to define a distinct subset of medium-spiny projection neurons, possibly of distinct function: those segregating within the striosomes and further contributing an axon to the direct pathway.
Finally, adult cholinergic interneurons continue to express SLITRK1; these are thought also to express Slit1 ( Regardless of the underlying specific cellular and molecular mechanisms, TS is clearly a developmental disorder. Our previous findings (Abelson et al., 2005) suggest that mutations in SLITRK1 could have a role in disease, and the present study places SLITRK1 in the neuroanatomical circuits most commonly associated with TS. It is premature to speculate on the consequences of SLITRK1 mutations on basal ganglia development and function. The detailed characterization of its highly developmentally regulated and evolutionarily conserved expression, however, points to components of the corticostriatal-thalamocortical pathway that could be affected at specific developmental time points critical for the elaboration of the circuitry. 
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